More interestingly, we identified TOX2 as a promising tumor biomarker, suggesting its possible role in gliomas development, with a differential expression in PAs with different brain localization and a more pronounced hypermethylation in glioblastomas. This evidence concerns the gene TOX2 and central nervous system cancer.